Literature DB >> 11812994

Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP.

Bénédicte Manoury1, Daniela Mazzeo, Lars Fugger, Nick Viner, Mary Ponsford, Heather Streeter, Graziella Mazza, David C Wraith, Colin Watts.   

Abstract

Little is known about the processing of putative human autoantigens and why tolerance is established to some T cell epitopes but not others. Here we show that a principal human HLA-DR2-restricted epitope--amino acids 85-99 of myelin basic protein, MBP(85-99)--contains a processing site for the cysteine protease asparagine endopeptidase (AEP). Presentation of this epitope by human antigen-presenting cells is inversely proportional to the amount of cellular AEP activity: inhibition of AEP in living cells greatly enhances presentation of the MBP(85-99) epitope, whereas overexpression of AEP diminishes presentation. These results indicate that central tolerance to this encephalitogenic MBP epitope may not be established because destructive processing limits its display in the thymus. Consistent with this hypothesis, AEP is expressed abundantly in thymic antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812994     DOI: 10.1038/ni754

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  61 in total

Review 1.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

2.  Healthy individuals have Goodpasture autoantigen-reactive T cells.

Authors:  Juan Zou; Sigrid Hannier; Lindsay S Cairns; Robert N Barker; Andrew J Rees; A Neil Turner; Richard G Phelps
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

3.  Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.

Authors:  Kazuyuki Kawamura; Katherine A McLaughlin; Robert Weissert; Thomas G Forsthuber
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

4.  Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation.

Authors:  Elfriede Dall; Hans Brandstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

Review 5.  Oxidative Modifications in Tissue Pathology and Autoimmune Disease.

Authors:  Mei-Ling Yang; Hester A Doyle; Steven G Clarke; Kevan C Herold; Mark J Mamula
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

6.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

Review 7.  Endolysosomal proteases and their inhibitors in immunity.

Authors:  Phillip I Bird; Joseph A Trapani; José A Villadangos
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

8.  Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response.

Authors:  Danielle B Ulanet; Michael Torbenson; Chi V Dang; Livia Casciola-Rosen; Antony Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

9.  Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.

Authors:  Rajesh Singh; Shailesh Singh; Praveen K Sharma; Udai P Singh; David E Briles; Susan K Hollingshead; James W Lillard
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

Review 10.  Granzyme B cleavage of autoantigens in autoimmunity.

Authors:  E Darrah; A Rosen
Journal:  Cell Death Differ       Date:  2010-01-15       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.